Connection
Robert Jotte to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Robert Jotte has written about Antineoplastic Agents, Immunological.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.028 |
|
|
|
-
Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). J Thorac Oncol. 2018 05; 13(5):682-688.
Score: 0.028